<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-13T04:24:29Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/13630" metadataPrefix="didl">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/13630</identifier><datestamp>2025-10-24T10:42:24Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>col_2072_378092</setSpec></header><metadata><d:DIDL xmlns:d="urn:mpeg:mpeg21:2002:02-DIDL-NS" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
   <d:DIDLInfo>
      <dcterms:created xmlns:dcterms="http://purl.org/dc/terms/" xsi:schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2025-10-24T10:42:24Z</dcterms:created>
   </d:DIDLInfo>
   <d:Item id="hdl_11351_13630">
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <dii:Identifier xmlns:dii="urn:mpeg:mpeg21:2002:01-DII-NS" xsi:schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:11351/13630</dii:Identifier>
         </d:Statement>
      </d:Descriptor>
      <d:Descriptor>
         <d:Statement mimeType="application/xml; charset=utf-8">
            <oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
               <dc:title>Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study</dc:title>
               <dc:creator>Bento, Leyre</dc:creator>
               <dc:creator>González-Sierra, Pedro Antonio</dc:creator>
               <dc:creator>Martínez Muñoz, Carmen</dc:creator>
               <dc:creator>Ortí Verdet, María Consejo</dc:creator>
               <dc:creator>Sorribes, Marina</dc:creator>
               <dc:creator>Peña Domingo, Marta</dc:creator>
               <dc:creator>Abrisqueta, Pau</dc:creator>
               <dc:creator>Rovira, Jordina</dc:creator>
               <dc:creator>Sitges, Marta</dc:creator>
               <dc:creator>Franch-Sarto, Mireia</dc:creator>
               <dc:creator>Mussetti, Alberto</dc:creator>
               <dc:creator>Sureda, Anna</dc:creator>
               <dc:creator>CABALLERO GONZÁLEZ, ANA CAROLINA</dc:creator>
               <dc:subject>Cèl·lules mare hematopoètiques - Trasplantació</dc:subject>
               <dc:subject>Limfomes - Tractament</dc:subject>
               <dc:subject>Cèl·lules B - Tumors - Tractament</dc:subject>
               <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation</dc:subject>
               <dc:subject>DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse</dc:subject>
               <dc:subject>Other subheadings::Other subheadings::/therapy</dc:subject>
               <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Transplantation::Transplantation, Autologous</dc:subject>
               <dc:subject>DISEASES::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Recurrence</dc:subject>
               <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre hematopoyéticas</dc:subject>
               <dc:subject>ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso</dc:subject>
               <dc:subject>Otros calificadores::Otros calificadores::/terapia</dc:subject>
               <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::trasplante::trasplante autólogo</dc:subject>
               <dc:subject>ENFERMEDADES::afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::recurrencia</dc:subject>
               <dc:description>Autologous stem cell transplantation; Large B-cell lymphoma</dc:description>
               <dc:description>Trasplante autólogo de células madre; Linfoma de células B grandes</dc:description>
               <dc:description>Trasplantament autòleg de cèl·lules mare; Limfoma de cèl·lules B grans</dc:description>
               <dc:description>We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as ≥3rd line (HR, 1.81; 95% CI, 1.42-2.31; P &lt; .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P &lt; .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P &lt; .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as ≥3rd line (HR, 1.77; 95% CI, 1.32-2.37; P &lt; .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P &lt; .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P &lt; .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.</dc:description>
               <dc:date>2025-10-24T10:42:24Z</dc:date>
               <dc:date>2025-10-24T10:42:24Z</dc:date>
               <dc:date>2025-09-09T10:31:54Z</dc:date>
               <dc:date>2025-09-09T10:31:54Z</dc:date>
               <dc:date>2025-07-08</dc:date>
               <dc:type>info:eu-repo/semantics/article</dc:type>
               <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
               <dc:identifier>http://hdl.handle.net/11351/13630</dc:identifier>
               <dc:relation>Blood Advances;9(13)</dc:relation>
               <dc:relation>https://doi.org/10.1182/bloodadvances.2024015415</dc:relation>
               <dc:rights>Attribution-NonCommercial-NoDerivatives 4.0 International</dc:rights>
               <dc:rights>http://creativecommons.org/licenses/by-nc-nd/4.0/</dc:rights>
               <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
               <dc:publisher>Elsevier</dc:publisher>
               <dc:source>Scientia</dc:source>
            </oai_dc:dc>
         </d:Statement>
      </d:Descriptor>
   </d:Item>
</d:DIDL></metadata></record></GetRecord></OAI-PMH>